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Abstract: A facile single-step preparation strategy for fabricating vancomycin 35 
functionalized organic polymer-based monolith within 100 μm fused-silica capillary 36 
was developed. The synthetic chiral functional monomer, i.e 2-isocyanatoethyl 37 
methacrylate (ICNEML) derivative of vancomycin, was co-polymerized with the cross-38 
linker ethylene dimethacrylate (EDMA) in the presence of methanol and dimethyl 39 
sulfoxide as the selected porogens. The co-polymerization conditions were 40 
systematically optimized in order to obtain satisfactory column performance. Adequate 41 
permeability, stability and column morphology were observed for the optimized 42 
poly(ICNEML-vancomycin-co-EDMA) monolith. A series of chiral drugs were 43 
evaluated on the poly(ICNEML-vancomycin-co-EDMA) monolith in either polar 44 
organic-phase or reversed-phase modes. After the optimization of separation conditions, 45 
baseline or partial enantioseparation were obtained for series of drugs including 46 
thalidomide, colchicine, carteolol, salbutamol, clenbuterol and several other β-blockers. 47 
The proposed single-step approach not only resulted in a vancomycin functionalized 48 
organic polymer-based monolith with good performance, but also significantly 49 
simplified the preparation procedure by reducing time and labor. 50 
 51 
 52 
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1. Introduction 58 
Although a large number of chiral stationary phases (CSPs) are available on the 59 
market, the development of novel CSPs still attracts considerable interest [1-2]. 60 
Recently, increasing efforts have been directed toward the development of organic 61 
polymer-based chiral monolithic columns because of their excellent permeability, pH 62 
stability, low resistance to mass transfer and high performance [3-4]. So far, various 63 
chiral selectors functionalized polymer-based chiral monoliths have been reported, such 64 
as cyclodextrin and its derivatives [5-6], quinidine and its derivatives [7-9], cellulose 65 
derivatives [10], proteins [11, 12], macrocyclic antibiotics [13-14], crown ethers [15] 66 
and chiral ion-exchangers [16]. 67 
Over the years, the vancomycin-type glycopeptide antibiotics have been proved to 68 
be a versatile class of chiral selectors for enantioseparation in polar organic-phase, 69 
normal-phase and reversed-phase modes since their enantioselectivity was 70 
demonstrated by Armstrong et al. [17]. However, very few vancomycin functionalized 71 
polymer-based monoliths have been reported. So far, only Maruška and coworkers 72 
developed a multi-step post-column modification strategy for immobilizing 73 
vancomycin onto the surface of organic polymeric monolith at the turn of the century 74 
[13-14]. The polymeric support was firstly prepared through in situ copolymerization 75 
of N-(hydroxymethyl) acrylamide, allyl glycidyl ether and piperazine diacrylamide 76 
with vinyl sulfonic acid within 100 μm I.D. capillaries. Subsequently, vancomycin was 77 
introduced onto the polymeric skeleton via reductive amination of the aldehyde groups 78 
converted from epoxy groups. Later on, they simplified the preparation procedure by 79 
replacing allyl glycidyl ether with N, N’-diallyltartardiamide, which can be easily 80 
cleaved into two aldehyde groups using periodate treatment. The vancomycin 81 
functionalized polymer-based monoliths prepared through both ways exhibited good 82 
enantioselectivity for racemic compounds in capillary electrochromatography (CEC). 83 
However, the authors did not provide any column-to-column and batch-to-batch 84 
repeatability data in their studies. To the best of our knowledge, there is no other report 85 
about vancomycin functionalized polymer-based monoliths. This may be partially 86 
attributed to some disadvantages associated with multi-step preparation strategy, such 87 
as time-consuming, laborious and probably dissatisfactory repeatability. Vancomycin 88 
functionalized silica-based monoliths were also prepared through multi-step 89 
preparation strategy [18-21]. Hsieh et al. recently developed a single-step in situ sol-90 
gel approach for preparing vancomycin functionalized silica-based monolith [22]. A 91 
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sol-gel precursor containing vancomycin was synthesized and copolymerized with 92 
skeleton precursor to form a porous silica-based monolith. The proposed single-step 93 
approach not only resulted in a chiral column with good efficiency and 94 
enantioselectivity for many basic enantiomers, but also significantly simplified the 95 
preparation procedure. Aiming at reducing the time and labor associated with the 96 
fabrication of vancomycin functionalized organic polymer-based monoliths, it would 97 
be of high interest to develop a single-step copolymerization approach as well. 98 
In this work, a chiral functional monomer, i.e 2-isocyanatoethyl methacrylate 99 
(ICNEML) derivative of vancomycin (ICNEML-vancomycin), was first synthesized. It 100 
was then in situ copolymerized with the cross-linker ethylene dimethacrylate (EDMA) 101 
in a binary porogen system of methanol and dimethyl sulfoxide (DMSO). The 102 
polymerization conditions were systematically optimized in order to obtain satisfactory 103 
permeability, column efficiency and enantioresolution. The enantioresolution capability 104 
of the optimized poly(ICNEML-vancomycin-co-EDMA) was evaluated by analyzing a 105 
series of chiral drugs in either polar organic-phase or reversed-phase modes. The 106 
enantioseparation conditions, including the organic solvent type and concentration, the 107 
buffer concentration and the pH of the mobile phase, were also carefully optimized. 108 
2. Materials and methods 109 
2.1. Reagents and samples 110 
2,2’-azobisisobutyronitrile (AIBN), 3-(trimethoxysilyl)-propylmethacrylate (γ-111 
MAPS), ethylene dimethacrylate (EDMA), 2-isocyanatoethyl methacrylate (ICNEML), 112 
DMSO, methanol (MeOH), ethanol, 1,4-butanediol, 1-propanol, tetrahydrofuran (THF), 113 
cyclohexane, 1-dodecanol and toluene, acetonitrile (ACN), triethylamine (TEA), acetic 114 
acid (HAc), pyridine, acetone and vancomycin hydrochloride were acquired from 115 
Aladdin Chemicals (Shanghai, China). Acebutolol, carteolol, sotalol, propranolol, 116 
pindolol, tertaolol, clenbuterol, salbutamol and thalidomide were obtained from Energy 117 
Chemical (Shanghai, China). Colchicine was purchased from Sigma (Missouri, USA). 118 
The fused-silica capillaries (375 μm O.D. × 100 μm I.D.) were obtained from Ruifeng 119 
Chromatography Ltd. (Hebei, China). Distilled water was purified using a Milli-Q 120 
system (Massachusetts, USA). Polar organic mobile phases were set up by mixing the 121 
desired ratio of ACN and MeOH, and then adding various amount of TEA and HAc. 122 
All mobile phases were subjected to filtration through a 0.22-μm membrane and 123 
sonication degas prior to use. 124 
2.2. Instrumentations 125 
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Molecular masses were determined on a Waters Synapt G2 TOF mass spectrometer 126 
(Milford, USA). A Jinghong DKS22 water bath (Shanghai, China) was used for 127 
thermally initiated copolymerization. Scanning electron microscopy (SEM) 128 
experiments were performed with a Zeiss Gemini ultra-55 SEM (Deutschland, 129 
Germany) at an acceleration voltage of 5 kV. All nano-LC experiments were conducted 130 
on a nano-LC instrument, laboratory assembled. The system consists of a DiNa nano 131 
gradient pump (Tokyo, Japan), a Shimadzu SPD-15C UV detector (Kyoto, Japan) with 132 
a lab-made on-column detection cell and a Valco four-port injection valve with 20 nL 133 
internal loop (Houston, USA). All data acquisition and analysis were carried out with 134 
Unimicro TrisepTM Workstation 2003 (Shanghai, China). The pH values of buffer 135 
solutions were measured by a Sartorius PB-10 pH meter (Göttingen, Germany).  136 
2.3. Synthesis of the chiral functional monomer ICNEML-vancomycin 137 
The nucleophilic addition of amine or hydroxyl groups were often used for the 138 
derivatization of vancomycin [23-24]. In this study, ICNEML was chosen as the 139 
derivatization reagent to modify vancomycin through the nucleophilic addition reaction. 140 
For the schematic representation of the synthesis of the novel ICNEML-vancomycin 141 
monomer, see Fig. 1. In brief, vancomycin hydrochloride (60 mg, 0.04 mmol) was 142 
dissolved in DMSO (0.3 mL). Then, pyridine (0.4 mL) and ICNEML (10 μL, 0.07 mmol) 143 
were added into the mixture and stirred for 24 h under nitrogen at room temperature. 144 
After adding acetone (8 mL) and stirring for another 10 min, a white precipitate was 145 
collected by centrifugation at 4000 rpm for 5 min and washed with acetone for five 146 
times. Finally, the precipitate was dried under vacuum to give the target monomer (light 147 
white solid). The molecular formula of ICNEML-vancomycin was established as 148 
C73H84N10O27Cl2 from its HR-ESI-MS (m/z: 1603.4965 [M+H]+, calculated for 149 
C73H85N10O27Cl2: 1603.4963) in Fig. S1. 150 
2.4. Preparation of the poly(ICNEML-vancomycin-co-EDMA) monolith columns 151 
Prior to the polymerization, the fused-silica capillaries were pretreated with γ-MAPS 152 
to provide the anchoring sites for the bulk polymer [25]. Then, the monomer ICNEML-153 
vancomycin, the binary porogens (DMSO and MeOH), the crosslinker EDMA and the 154 
initiator AIBN were accurately weighted and mixed into a homogenous solution in a 2 155 
mL of vial. The mixture was sonicated and degassed for 5 min, and then introduced into 156 
20 cm long pretreated capillaries. Both ends of the capillaries were sealed with rubber 157 
plugs and submerged into the water bath at 60 oC for 12 h. The unreacted porogens and 158 
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chemicals were removed by flushing the column with methanol. The obtained monolith 159 
was cut to 15 cm for nano-LC analysis. A 2-5 mm length of the monolith was used for 160 
scanning electron microscopy (SEM) analysis. 161 
3. Results and discussion 162 
3.1. Preparation and characterization of the poly(ICNEML-vancomycin-co-163 
EDMA) monolithic column  164 
Porogen selection is a critical step in the preparation of polymer-based monolithic 165 
column since the type and amount of porogens influence the porosity, morphology, 166 
permeability and even the chromatographic efficiency of the monolith. A suitable 167 
porogenic solvent or solvent combination should be able to dissolve all components 168 
(including functional monomer, initiator and cross-linker) and does not react each other 169 
chemically. In this study, several commonly used polar solvents (DMSO, water, MeOH, 170 
ethanol, 1,4-butanediol and 1-propanol) and non-polar solvents (THF, cyclohexane, 171 
toluene, 1-dodecanol) were initially investigated. The solubility of monomers, the 172 
permeability and visual appearance of the monoliths prepared under each porogen 173 
system were inspected using nano-LC and microscopy. Based upon our initial 174 
experiments, both ICNEML-vancomycin and EDMA showed good solubility in a 175 
binary solvent system consisting of MeOH and DMSO (75/25, w/w). In addition, the 176 
resulting monoliths also exhibited a uniform dark structure and good permeability. 177 
Therefore, these solvents were selected for the following systematical optimization of 178 
the polymerization conditions, including the weight fraction of the porogens, the weight 179 
fraction of EDMA and the composition of porogenic mixture. Acebutolol was selected 180 
as test analyte using a mobile phase consisting of MeOH/ACN/TEA/HAc 181 
(80/20/0.08/0.02, v/v/v/v). The influence of the porogen content was first studied by 182 
varying the weight fraction of MeOH/ DMSO (75/25, w/w) at three different percentage, 183 
i.e. 71% (Column C1), 75% (Column C2) and 79% (Column C3), while keeping 184 
constant the other conditions (see Table 1). The results showed that the porogens 185 
content had a significant influence on the column permeability. As the percentage of 186 
porogens increased, the backpressure diminished. The column C1 prepared with 71% 187 
porogens exhibited a very high backpressure. When comparing the enantioresolution 188 
obtained for acebutolol enantiomers, the column C2 exhibited a higher 189 
enantioresolution, and therefore, it was selected for the following studies. 190 
 Second, the content of the crosslinker EDMA in the monomer mixture was 191 
optimized since it can also influence both the column permeability and 192 
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enantioselectivity. As the weight fraction of EDMA in the monomer mixture increased 193 
from 20.8% (column C5) to 25.0% (column C2), the back-pressure and 194 
enantioresolution dramatically increased from 3.6 to 7.5 MPa and 0.51 to 1.45, 195 
respectively. However, further increasing the EDMA content to 29.2 % (column C4) 196 
resulted in a slightly lower Rs value (1.38) and higher backpressure (9.5 MPa) when 197 
compared to column C2. Thus, 25.0 % EDMA was considered for further optimizations. 198 
Finally, the influence of the porogenic mixture composition (MeOH and DMSO) was 199 
investigated by varying the weight content of MeOH from 70% (column C6) to 80% 200 
(column C7). The increase of the MeOH content caused a decrease of the back-pressure 201 
from 9.8 to 4.7 MPa. 75 % MeOH (column C2) allowed for the highest Rs value under 202 
a reasonable backpressure.  203 
Based on these optimization experiments, the polymerization mixture containing 25% 204 
monomers (ICNEML-vancomycin/EDMA, 75/25, w/w) and 75% porogens 205 
(MeOH/DMSO, 75/25, w/w) were selected for following studies. The morphology of 206 
the optimized poly (ICNEML-vancomycin-co-EDMA) (column C2) monolithic 207 
column was evaluated by scanning electron microscopy (SEM). As shown in Fig. 2, 208 
the SEM images indicated that the column C2 has a morphology of continuous skeleton 209 
and large through-pores, and the monolithic rod is tightly anchored on the inner wall of 210 
the capillary column.  211 
3.2. Permeability and reproducibility of the poly(ICNEML-vancomycin-co-212 
EDMA) monolithic column 213 
The permeability K of a monolithic column can be calculated according to the 214 
following equation [26-27]:  215 
𝐾 =
𝑢ηL
ΔP
 216 
where u is the linear velocity of the mobile phase, L is the length of the column, ΔP 217 
is the pressure drop across the column, and η is the dynamic viscosity of the eluent. 218 
Toluene (ACN or MeOH as mobile phase) and thiourea (water/ACN (50/50, v/v) as 219 
mobile phase) were chosen as the dead time markers. As shown in Table 2, the 220 
calculated K values for the column C2 were 2.78 × 10-14, 4.16 × 10-14 and 1.97 × 10-14 221 
m2 when using MeOH, ACN and water/ACN (50/50, v/v) as the mobile phases, 222 
respectively. It is worth noting that these determined permeability values are quite 223 
similar, indicating the swell or shrink of the optimized poly(ICNEML-vancomycin-co-224 
EDMA) monolith in solvents with different polarities is little.  225 
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Repeatability and reproducibility of some studied parameters on the poly (ICNEML-226 
vancomycin-co-EDMA) monolithic column were evaluated through calculating the 227 
RSD values for k1, k2, α and Rs of the racemic test compound acebutolol using a mixture 228 
of MeOH/ACN/TEA/HAc (85/15/0.08/0.02, v/v/v/v) as mobile phase (Table 3). The 229 
column-to-column reproducibility (n=6) for retention factors (k1 and k2) were 2.36%, 230 
while the batch-to-batch (n=6) RSD values were 2.72% and 2.36%. The run-to-run 231 
repeatability (n=6) for k1 and k2 was also adequate with RSD values of 1.98% and 232 
2.36%, in addition to day-to-day repeatability (n=6) which RSD values were 3.03% and 233 
3.42%, respectively. RSD values of α and Rs were also satisfactory (≤ 5.92%). These 234 
data demonstrated that the poly (ICNEML-vancomycin-co-EDMA) monolithic column 235 
has a satisfactory reproducibility for enantioseparation in nano-LC. 236 
3.3. Application of the poly(ICNEML-vancomycin-co-EDMA) monolithic column 237 
3.3.1. Polar organic phase mode 238 
Based on our experience and on the data reported in literature [28] a mobile phase 239 
containing ACN-MeOH and TEA-HAc was selected as polar organic mobile phase. It 240 
has been reported that in any LC-based enantioseparation, the composition of mobile 241 
phase affects the enantioselectivity through changing the charge-charge interaction, 242 
hydrogen bonding and π-π interaction, among other factors [29-30]. Therefore, the 243 
MeOH/ACN content and additives content (TEA/HAc ratio and their total 244 
concentration) were modified to evaluate their effect on the enantioresolution of 245 
carteolol, acebutolol and sotalol. Due to the fact that the observed behavior was quite 246 
the same for these three compounds, only figure of merits for carteolol will be shown. 247 
The influence of the concentration ratio of MeOH/ACN on the retention factor and 248 
enantioresolution for carteolol was evaluated by keeping constant TEA/HAc content. 249 
As shown in Fig. 3a and b, with increasing MeOH concentration from 60% to 85 % 250 
(v/v), the enantioresolution increased reaching its maximum value, and then decreased 251 
when the MeOH concentration further raised from 85% to 100% (v/v). The retention 252 
factor (k1) decreased gradually with the increase of the concentration of MeOH. On the 253 
other hand, the enantioselectivity factor (α) increased by raising MeOH content, while 254 
the column efficiency increased with the increase of MeOH content from 60% to 90% 255 
(v/v) and then diminished at 100% (v/v). As a compromise between enantioresolution 256 
and column efficiency, 85% (v/v) MeOH was chosen as the mobile phase. These results 257 
also agreed with the previous studies on the vancomycin based chiral stationary phases 258 
[22] because higher MeOH content in combination with a small amount of acid/base 259 
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additives might contribute to less nonselective hydrogen bonding interactions for 260 
carteolol enantiomers and vancomycin stationary phases. 261 
As can be observed in Fig. 4a, the use of an appropriate TEA/HAc concentration and 262 
ratio could be of paramount importance in influencing both enantioseparation and 263 
column efficiency. Therefore, the ratio of the TEA/HAc (%, v/v) in the mobile phase 264 
was varied from1:3 to 9:1, while the total concentration of TEA and HAc was kept at 265 
0.1% (v/v) and the ratio of MeOH/ACN kept constant at (85/15, v/v). The increase of 266 
the ratio of TEA/HAc from 1:3 to 4:1 caused an increase of enantioresolution. Then 267 
this parameter decreased as the ratio further increased to 9:1. This is because the 268 
hydrogen bonding is the most important in this mode, so the stronger interaction 269 
between the CSP and enantiomer with the Ac- content decreased in the mobile phase. 270 
However, the ionization of the basic compounds was weak as the TEA/HAc ratio 271 
increased from 4:1 to 9:1, and this would weaken the interaction. On the contrary, the 272 
chromatographic efficiency showed a different trends (decreased almost linearly by 273 
increasing the TEA/HAc ratio from 1:3 to 9:1). As a compromise to achieving optimum 274 
enantioresolution and column chromatographic efficiency, the ratio of 4:1 for 275 
TEA/HAc (0.08%/0.02%, v/v) was chosen as the mobile phase additive. 276 
Fig. 4b shows the effect of total concentration of TEA and HAc on the column 277 
efficiency. As can be seen, the increase of the total concentration of TEA and HAc in 278 
the mobile phase from 0.01% to 0.2% (v/v) caused a raising of number of theoretical 279 
plates, while the highest enantioresolution was obtained at 0.1 % (v/v). Therefore, a 280 
total concentration of TEA and HAc of 0.1% (v/v) was selected as the optimum mobile 281 
phase modifier mixture. 282 
Under the optimal conditions (mobile phase consisting of MeOH/ACN/TEA/HAc 283 
(85/15/0.08/0.02, v/v/v/v)), eight racemic compounds were tested. As shown in Table 284 
4 and Fig. 5, good Rs values were obtained for most of the compounds. 285 
3.3.2. Reversed phase mode 286 
As reported in previous studies [13, 14], the basic compound carteolol was not 287 
enantio-resolved on the vancomycin functionalized monolith in the reversed phase 288 
elution mode where ACN was mainly used [22]. In our preliminary experiments, no 289 
enantioresolution of this analyte was observed employing similar conditions. Therefore, 290 
MeOH instead of ACN was chosen for the enantioseparation of carteolol to investigate 291 
the effect of MeOH concentration on the enantioseparation of carteolol. As shown in 292 
Fig. 6a, both retention factor (k1) and enantioselectivity factor (α) increased by varying 293 
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MeOH content in the mobile phase in the range 80-98 % (v/v) with the highest values 294 
at 98 % (v/v). This effect can be explained with a consequent stronger interaction of the 295 
studied enantiomers with vancomycin CSP because higher MeOH concentration 296 
combined with TEAA would lead to less nonselective hydrogen interaction [14]. As 297 
shown in Fig. 6b, the MeOH content also had a strong influence on the 298 
enantioresolution and column efficiency, and a slightly higher enantioresolution and 299 
column efficiency was obtained when the mobile phase contained 90% (v/v) MeOH. 300 
Hence, 90% (v/v) MeOH was selected as the optimum mobile phase for the 301 
enantioseparation of carteolol. 302 
Due to the fact that in reversed phase mode the pH and content of buffer solution also 303 
played an important role for enantioseparation, they were investigated. Fig. 7a shows 304 
the effect of the buffer pH present in the mobile phase on enantioresolution and column 305 
chromatographic efficiency. Both parameters increased with increasing the buffer pH 306 
value from 4.5 to 6.0 and the optimum pH value was 5.5. In order to improve the 307 
enantioseparation, various concentration of TEAA buffer were evaluated (Fig. 7b). A 308 
decrease of the enantioresolution factors with increasing TEAA buffer content can be 309 
observed, while the column chromatographic efficiency raised when the TEAA buffer 310 
content increased from 0.1% to 1% (v/v) and then decreased. As a compromise between 311 
enantioresolution and column efficiency, 0.5% TEAA (pH=5.5)/MeOH (10/90, v/v) 312 
was selected as the mobile phase. Carteolol enantiomers were baseline separated with 313 
Rs value of 1.59 as shown in Fig. 8a. Clenbuterol, salbutamol, acebutolol and several 314 
other β-blockers were also tested using 0.5% TEAA (pH=5.5)/MeOH (10/90, v/v) as 315 
the mobile phase. However, it was found that the enantioresolutions of these 316 
compounds were not satisfactory. 317 
Colchicine was also tested under the above optimized conditions, unfortunately, no 318 
baseline enantioseparation was achieved. Therefore, a similar optimization process was 319 
performed. Under the optimized condition, i.e. 50 mM ammonium acetate 320 
(pH=5.5)/water/ACN (5/5/90, v/v/v), a baseline separation with Rs value of 2.92 was 321 
obtained for colchicine enantiomers (Fig. 8b). Due to the fact that thalidomide 322 
enantiomers were separated in previous reports using 0.2 % TEAA, pH 4.5/ACN (80:20, 323 
v/v) as mobile phase [22], these conditions were employed for the separation of 324 
thalidomide on the poly (ICNEML-vancomycin-co-EDMA) monolith column. It was 325 
found that the enantioresolution was still good (3.27) but the analysis time was too long 326 
(≥80 min). Thus, the mobile phase was re-optimized in which 0.5% TEAA buffer 327 
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(pH=5.4)/ACN (70/30, v/v) offered the best output in terms of enantioresolution and 328 
analysis time (Fig. 8c). As shown in Table 5, carteolol, colchicine and thalidomide 329 
enantiomers can be completely separated on the poly (ICNEML-vancomycin-co-330 
EDMA) monolith column under the reversed-phase mode by nano-LC. 331 
4. Conclusion 332 
This study has demonstrated a novel and facile method to synthesize vancomycin 333 
functionalized organic polymeric monolith through a single-step approach, which 334 
simplifies the fabrication of previous studies. The prepared monolith has been proven 335 
to possess large through-pores and a good mechanical stability. Satisfactory column 336 
permeability and good enantioselectivity were obtained on the optimum 337 
poly(ICNEML-vancomycin-co-EDMA) monolith. The mobile phase composition of 338 
different buffer pH, organic modifier content and buffer concentration which could 339 
influence the enantioseparation was further investigated both in the polar organic and 340 
reversed phase modes for enantioseparation of β-blockers. The vancomycin 341 
functionalized organic polymer monolith displayed baseline separation for most of the 342 
selected enantiomers in both chromatographic modes.  343 
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Figures captions: 461 
Fig. 1. Schematic representation of the synthesis of the ICNEML-vancomycin. 462 
 463 
Fig. 2. SEM images of the poly (ICNEML-vancomycin-co-EDMA) monolithic column 464 
at different magnifications. 465 
 466 
Fig. 3. Effect of the MeOH content on (a) retention factor and enantioselectivity; (b) 467 
enantioresolution and column chromatographic efficiency for carteolol enantiomers in 468 
the polar organic-phase mode. Conditions: column dimensions: 15 cm × 100 μm I.D.; 469 
mobile phase: MeOH/ACN/TEA/HAc (at the desired ratio of MeOH and 470 
ACN/0.08/0.02, v/v/v/v); UV detection wavelength: 230 nm; total flow rate: 400 471 
nL/min; injection volume: 20 nL. 472 
 473 
Fig. 4. Effect of the ratio (a) and content (b) of TEA/HAc on enantioresolution and 474 
column chromatographic efficiency for carteolol enantiomers in the polar organic-475 
phase mode. Conditions: mobile phase: (a) MeOH/ACN/TEA/HAc (85/15/at the 476 
desired ratio of TEA and HAc, v/v/v/v); (b) MeOH/ACN/TEA/HAc (85/15/at the 477 
desired content of TEA and HAc, v/v/v/v); other experimental conditions are the same 478 
as in Fig. 3. 479 
 480 
Fig. 5. Enantioseparation of racemic compounds in polar organic-phase mode. 481 
Conditions: column dimensions: 15 cm × 100 μm I.D.; mobile phase: 482 
MeOH/ACN/TEA/HAc (85/15/0.08/0.02, v/v/v/v); UV detection wavelength: 230 nm; 483 
total flow rate: 400 nL/min; injection volume: 20 nL. 484 
 485 
Fig. 6. Effect of the MeOH content on (a) retention factor (k1) and enantioselectivity 486 
factor (α); (b) enantioresolution and column chromatographic efficiency for carteolol 487 
enantiomers in the reversed-phase mode. Conditions: column dimensions: 15 cm × 100 488 
μm I.D.; mobile phase: 0.5% TEAA, pH=5.5/MeOH; UV detection wavelength: 230 489 
nm; total flow rate: 400 nL/min; injection volume: 20 nL. 490 
 491 
Fig. 7. Effect of TEAA buffer pH (a) and content (b) on enantioresolution and column 492 
chromatographic efficiency for carteolol enantiomers in the reversed-phase mode. 493 
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Conditions: mobile phase: (a) 0.5% TEAA/MeOH (10/90, v/v); (b) TEAA, 494 
pH=5.5/MeOH (10/90, v/v); other experimental conditions are the same as in Fig. 6. 495 
 496 
Fig. 8. Enantioseparation of (a) carteolol, (b) colchicine and (c) thalidomide in 497 
reversed-phase mode. Conditions: column dimensions: 15 cm × 100 μm I.D.; mobile 498 
phase: (a) 0.5% TEAA, pH=5.5/MeOH (10/90, v/v); (b) 50 mM ammonium acetate, 499 
pH=5.5/water/ACN (5/5/90, v/v/v); (c) 0.5% TEAA, pH=5.4/ACN (70/30, v/v); UV 500 
detection wavelength: 230 nm (a and c) or 243 nm (b); flow rate: 400 nL/min; injection 501 
volume: 20 nL.  502 
 503 
 504 
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Table 1. Composition of the polymerization mixture used for the preparation of the poly (ICNEML-vancomycin-co-EDMA) monolith columns and their properties.  
 
 
 
Conditions: column dimensions: 15 cm × 100 μm I.D.; mobile phase: MeOH/ACN/TEA/HAc (80/20/0.08/0.02, v/v/v/v); UV detection wavelength: 230 nm; total flow 
rate: 400 nL/min; injection volume: 20 nL; sample: acebutolol. 
 
  
Column 
Monomers (%, w/w)  Porogens (%, w/w)  Monomers: Porogens (%, w/w) 
Backpressure  
(MPa) 
Enantioreso
lution 
ICNEML-
vancomycin 
EDMA  MeOH DMSO  Monomers Porogens 
C1 75.0 25.0  75.0 25.0  29.0 71.0 Too high / 
C2 75.0 25.0  75.0 25.0  25.0 75.0 7.5 1.45 
C3 75.0 25.0  75.0 25.0  21.0 79.0 3.4 0.37 
C4 70.8 29.2  75.0 25.0  25.0 75.0 9.5 1.38 
C5 79.2 20.8  75.0 25.0  25.0 75.0 3.6 0.51 
C6 75.0 25.0  70.0 30.0  25.0 75.0 9.8 0.58 
C7 75.0 25.0  80.0 20.0  25.0 75.0 4.7 0.94 
Table 2. Permeability of the poly (ICNEML-vancomycin-co-EDMA) monolith column 
 
  
 
 
 
 
 
 
Relative polarity and viscosity data of pure liquids were obtained from Ref. [26-27] 
  
  
Mobile phase Relative polarity Viscosity ƞ (×10-3 Pa·s) Permeability K (×10-14 m2) 
ACN/H2O (50/50) / 0.820 1.97 
MeOH 0.762 0.544 2.78 
ACN 0.460 0.369 4.16 
Table 3. Reproducibility of the poly (ICNEML-vancomycin-co-EDMA) monolith columns 
 
 
Average retention factor (RSD) Average selectivity 
α (RSD) 
Average resolution 
Rs (RSD) k1 k2 
Column to column (n=6) 1.31 (2.36%) 1.53 (2.36%) 1.17 (2.02%) 1.40 (5.92%) 
Run to run (n=6) 1.27 (1.98%) 1.46 (2.36%) 1.15 (1.57%) 1.42 (4.14%) 
Day to day (n=6) 1.25 (3.03%) 1.51 (3.42%) 1.21 (1.13%) 1.44 (4.72%) 
Batch to batch (n=6) 1.29 (2.72%) 1.49 (2.36%) 1.16 (1.79%) 1.39 (5.33%) 
 
Conditions: column dimensions: 15 cm × 100 μm I.D.; mobile phase: MeOH/ACN/TEA/HAc (85/15/0.08/0.02, v/v/v/v); UV detection wavelength: 230 nm; total flow 
rate: 400 nL/min; injection volume: 20 nL; sample: acebutolol. 
 
Table 4. Enantioseparation of eight racemic compounds under the polar organic phase mode. 
 
Sample k1 k2 α Rs N1 (m) N2 (m) 
Carteolol 1.04 1.28 1.23 1.45 4500 4100 
Propranolol 1.04 1.21 1.17 1.38 5100 4300 
Acebutolol 1.26 1.48 1.17 1.43 4400 3900 
Pindolol 1.07 1.23 1.15 1.32 3900 3200 
Tertaolol 0.66 0.81 1.22 1.39 5500 4600 
Sotalol 1.65 2.01 1.22 1.42 4100 3300 
Clenbuterol 0.67 0.78 1.16 1.26 4600 4100 
Salbutamol 0.74 0.88 1.18 1.47 4900 4100 
 
Experimental conditions are the same as in Fig. 4. 
 
  
Table 5. Enantioseparation of three racemic compounds under the reversed phase mode. 
 
Sample k1 k2 α Rs N1 (m) N2 (m) 
Carteolol 2.18 2.72 1.24 1.59 3800 2500 
Colchicine 0.41 1.08 2.62 2.92 6200 3300 
Thalidomide 0.52 1.33 2.55 2.85 5100 4200 
 
Experimental conditions are the same as in Fig. 7. 
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Figure S1. HR-ESI-MS of ICNEML-vancomycin. 
 
 
